<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="73">
  <stage>Registered</stage>
  <submitdate>25/07/2005</submitdate>
  <approvaldate>9/08/2005</approvaldate>
  <actrnumber>ACTRN12605000099628</actrnumber>
  <trial_identification>
    <studytitle>FEASIBILITY STUDY OF PREOPERATIVE TAC IN CONJUNCTION WITH THE DEVELOPMENT OF A STANDARD PROTOCOL FOR THE MANAGEMENT OF LOCALLY ADVANCED BREAST CANCER</studytitle>
    <scientifictitle>FEASIBILITY STUDY OF PREOPERATIVE TAC (DOCETAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE) IN CONJUNCTION WITH THE DEVELOPMENT OF A STANDARD PROTOCOL FOR THE MANAGEMENT OF LOCALLY ADVANCED BREAST CANCER (XRP6976D/6164)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast cancer Locally advanced</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 cycles of TAC chemotherapy given pre-operatively and in responding patients, followed by surgery then radiation therapy.</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of complete pathological response following surgery</outcome>
      <timepoint>surgery</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Feasibility of delivering 6 cycles of TAC followed by surgery within 21 days and subsequently radiation therapy</outcome>
      <timepoint>30 days after last dose of chemo</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of response by 1) Breast MRI and 2) PET scan.</outcome>
      <timepoint>post treatment but prior to surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Breast cancer T3Nany, T4Nany, N2 or N3 M0, ECOG performance status 0-2, Normal cardiac function.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No metastases, Peripheral neuropathy &gt; grade 2.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/04/2005</anticipatedstartdate>
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/11/2006</actualenddate>
    <samplesize>34</samplesize>
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Arlene Chan</primarysponsorname>
    <primarysponsoraddress>Suite 41/ 146 Mounts Bay Road Perth WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Investigator initiated pharmaceutical grant</fundingname>
      <fundingaddress>unknown / trial archived</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Sanofi-Aventis</sponsorname>
      <sponsoraddress>unknown / trial documents archived</sponsoraddress>
      <sponsorcountry>France</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This will be a single arm, multicentre study involving women diagnosed with non-metastatic locally advanced breast cancer. The study will assess the feasibility of developing a uniform approach with chemotherapy, surgery and radiation therapy in the treatment of locally advanced breast cancer. It will also define the rates of objective clinical response and complete pathological response following 6 cycles TAC. Further, the accuracy of breast MRI and PET in predicting extent of breast cancer in the pathological examination of the surgical specimen will be assessed.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mount Hospital, Perth</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/02/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital, Perth</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr Arlene Chan</name>
      <address>41 146 Mounts Bay Rd
Perth WA 6000</address>
      <phone>+61 8 9481 4522</phone>
      <fax />
      <email>arlenechan@me.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Astrid Bauwens</name>
      <address>Breast Cancer Research Centre - WA
Suite 40, 146 Mounts Bay Road
Perth WA 6000</address>
      <phone>+61 8 9483 46643</phone>
      <fax />
      <email>astrid.bauwens@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Astrid Bauwens</name>
      <address>BCRC-WA
Suite 40, 146 Mounts Bay Road
Perth WA 6000</address>
      <phone>+61 8 94834643</phone>
      <fax>+61 8 9483 4626</fax>
      <email>astrid.bauwens@bcrc-wa.com.au</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Arlene Chan</name>
      <address>Breast Cancer Research Centre - WA
Suite 41, 146 Mounts Bay Road
Perth WA 6000</address>
      <phone>+61 8 9481 4522</phone>
      <fax />
      <email>arlenechan@me.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>